Tissue Regeneration Therapeutics Inc. (TRT) raises $3.25 Million to accelerate the development of its Mesenchymal Cell therapeutics platform

Toronto, Canada, July 10th 2013: Tissue Regeneration Therapeutics Inc. (TRT) today
announced it has entered into a structured royalty sale transaction with SWK Holdings
Corporation. The transaction, valued at US$3.25 million, was based on the strength of two
TRT technology licenses in the family cord banking services sector. Toronto-based, Sapient
Capital Partners, acted as strategic and financial advisor to TRT.

TRT is a progressive biotechnology company with a focus on the commercial development
of our patented Human Umbilical Cord PeriVascular Cell (HUCPVC) platform
technology. TRT has discovered the world’s richest source of mesenchymal stromal cells
(MSCs) with potent regenerative, angiogenic, anti-inflammatory, immuno-regulatory and
anti-bacterial properties. Unique advantages of the TRT platform HUCPVC technology are
founded on the highly enriched source of these important cells compared to other tissue
sources. Specifically, HUCPVCs represent high cell yields at harvest from tissue normally
discarded at birth; high frequencies of mesenchymal stromal cells within the harvested
population, their increased biological potential compared to cells derived from adult tissues
and their inexhaustible supply.

About TRT
TRT is a Canadian Controlled Private Corporation (CCPC) with a focus on the commercial
development of their patented Human Umbilical Cord PeriVascular Cell (HUCPVC)
platform technology. TRT is the first company in the world to have issued and allowed
patents in the USA, Europe and Australasia, for extraction of these unique cells from
umbilical cord tissue. TRT provides license opportunities to collaborating partner
companies in the family banking, regenerative medicine and defense sectors. Additional
information is available at

About SWK Holdings Corporation
SWK Holdings Corporation (OTCQB: SWKH) (“SWK”) is a specialized finance company
with a focus on the global healthcare sector. SWK partners with ethical product marketers
and royalty holders to provide flexible financing solutions at an attractive cost of capital to
create long-term value for both SWK’s business partners and its investors. SWK believes its
financing structures achieve an optimal partnership for companies, institutions and inventors
seeking capital for expansion or capital and estate planning by allowing its partners to
monetize future cash flow with minimal dilution to their equity stakes. Additional
information on the life science finance market is available on the Company’s website

Write a comment